MCM
LEXX icon

MAI Capital Management’s Lexaria Bioscience LEXX Stock Holding History

MAI Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200
Closed -$124 – 5093
2025
Q4 		$124 Buy
+200
New +$189 ﹤0.01% 4136

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return

MAI Capital Management's LEXX Position: Q1 2026 in Review

MAI Capital Management sold out of Lexaria Bioscience (LEXX) in Q1 2026, closing a stake of 200 shares — an estimated $124 sold.

MAI Capital Management first reported a position in LEXX in Q4 2025 and held it in 1 quarter. The position peaked at $124 in Q4 2025. 28 funds tracked by Wall St. Rank hold LEXX as of Q1 2026.

  • MAI Capital Management reported no remaining Lexaria Bioscience position as of Q1 2026 after selling out during the quarter.
  • MAI Capital Management sold 200 Lexaria Bioscience shares in Q1 2026, an estimated $124.
  • MAI Capital Management first reported a position in Lexaria Bioscience in Q4 2025 and held it in 1 quarter.
  • MAI Capital Management's Lexaria Bioscience position peaked at $124 in Q4 2025.
  • 28 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.